Mechanism of Action
Somatostatin receptor agonism (primarily SSTR2/SSTR5). Inhibits GH, glucagon, insulin secretion. Suppresses GI hormone release and splanchnic blood flow.
Clinical Use
Acromegaly, carcinoid syndrome, VIPoma, GI bleeding. Mechanistic anchor and inhibitory counterpart to GH secretagogues.
Contraindications
Gallbladder disease. Diabetes (affects insulin/glucagon balance). Cardiac conduction abnormalities.
Evidence Summary
35+ years clinical use in acromegaly, carcinoid syndrome, and GI disorders. First oral somatostatin analog approved (Mycapssa, 2020).
Key Studies
- 1.CHIASMA OPTIMAL Trial, JCEM 2020 — IGF-1 normalization 58.2% vs 19.4% placebo (p=0.008). GH <2.5 ng/mL in 77.7% vs 30.4% (p=0.0007). Phase III RCT
- 2.ACROINNOVA Phase III — SC depot superior biochemical control, ~5x higher bioavailability than IM. 52-week sustained improvement
Evidence Gaps
Mechanistic counterpart to GH secretagogues — inhibitory vs stimulatory. Not interchangeable.
Emerging Research
Novel oral formulations expanding. Neuroendocrine tumor applications broadening.